Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
News provided by
Share this article
Share this article
IRVINE, Calif., Dec. 10, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) will discuss the company's strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance today during its annual investor conference.
Highlights
Presenting long-term strategic initiatives and growth outlook
Projecting 2021 global sales of $4.9-5.3 billion; underlying growth in the mid-teens
Projecting 2021 TAVR sales of $3.2-3.6 billion; underlying growth 15-20%
Estimating 2021 adjusted earnings per share $2.00-2.20
"Putting patients first has never been more important than it is in 2020, and I am humbled by the agility, resourcefulness and passion of our partners and employees in maintaining their important work on behalf of patients during this particularly difficult time," said Michael A. Mussallem, chairman and CEO. "Although we expect the pandemic to have a continuing impact on the global healthcare system, we are very optimistic about 2021 and we anticipate returning to strong, double-digit top-line growth. At the same time, we continue to aggressively pursue breakthrough therapies for the millions of patients with structural heart diseases and critical illnesses, which will help patients and result in success at Edwards in the years ahead."